---
document_datetime: 2025-12-02 06:47:59
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/prepandemic-influenza-vaccine-h5n1-surface-antigen-inactivated-adjuvanted-novartis-vaccines-diagnostics.html
document_name: prepandemic-influenza-vaccine-h5n1-surface-antigen-inactivated-adjuvanted-novartis-vaccines-diagnostics.html
version: success
processing_time: 0.080867
conversion_datetime: 2025-12-24 19:48:28.426505
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Prepandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics

[RSS](/en/individual-human-medicine.xml/65419)

##### Expired

This medicine's authorisation has expired

prepandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Medicine Human Expired

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

The marketing authorisation for Prepandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostic expired on 28 November 2015 following the decision of the marketing authorisation holder, Novartis Vaccines and Diagnostics S.r.l., not to apply for a renewal of the marketing authorisation.

The vaccine contained haemagglutinin and neuraminidase of influenza virus H5N1 A/Vietnam/1194/2004. Novartis Vaccines and Diagnostics S.r.l. (now named Seqirus) confirmed that it did not apply for renewal of the authorisation due to lack of demand for this product.

Prepandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostic was granted marketing authorisation in the European Union (EU) on 29 November 2010 for immunisation against the H5N1 subtype of influenza A virus. The marketing authorisation was valid for a 5-year period.

Prepandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostic was a duplicate application to Aflunov, which is authorised in the EU. The marketing authorisation holder (Seqirus) will maintain the marketing authorisation for Aflunov.

The European Public Assessment Report (EPAR) for Prepandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostic is updated accordingly to reflect the fact that the marketing authorisation is no longer valid.

Prepandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics : EPAR - Summary for the public

Reference Number: EMA/CHMP/670965/2010

English (EN) (204.04 KB - PDF)

**First published:** 24/01/2011

**Last updated:** 24/01/2011

[View](/en/documents/overview/prepandemic-influenza-vaccine-h5n1-surface-antigen-inactivated-adjuvanted-novartis-vaccines-and-diagnostics-epar-summary-public_en.pdf)

[Other languages (21)](#file-language-dropdown-20)

български (BG) (359.19 KB - PDF)

**First published:**

24/01/2011

**Last updated:**

24/01/2011

[View](/bg/documents/overview/prepandemic-influenza-vaccine-h5n1-surface-antigen-inactivated-adjuvanted-novartis-vaccines-and-diagnostics-epar-summary-public_bg.pdf)

español (ES) (265.22 KB - PDF)

**First published:**

24/01/2011

**Last updated:**

24/01/2011

[View](/es/documents/overview/prepandemic-influenza-vaccine-h5n1-surface-antigen-inactivated-adjuvanted-novartis-vaccines-and-diagnostics-epar-summary-public_es.pdf)

čeština (CS) (261.95 KB - PDF)

**First published:**

24/01/2011

**Last updated:**

24/01/2011

[View](/cs/documents/overview/prepandemic-influenza-vaccine-h5n1-surface-antigen-inactivated-adjuvanted-novartis-vaccines-and-diagnostics-epar-summary-public_cs.pdf)

dansk (DA) (205.65 KB - PDF)

**First published:**

24/01/2011

**Last updated:**

24/01/2011

[View](/da/documents/overview/prepandemic-influenza-vaccine-h5n1-surface-antigen-inactivated-adjuvanted-novartis-vaccines-and-diagnostics-epar-summary-public_da.pdf)

Deutsch (DE) (270.31 KB - PDF)

**First published:**

24/01/2011

**Last updated:**

24/01/2011

[View](/de/documents/overview/prepandemic-influenza-vaccine-h5n1-surface-antigen-inactivated-adjuvanted-novartis-vaccines-and-diagnostics-epar-summary-public_de.pdf)

eesti keel (ET) (267.17 KB - PDF)

**First published:**

24/01/2011

**Last updated:**

24/01/2011

[View](/et/documents/overview/prepandemic-influenza-vaccine-h5n1-surface-antigen-inactivated-adjuvanted-novartis-vaccines-and-diagnostics-epar-summary-public_et.pdf)

ελληνικά (EL) (369.82 KB - PDF)

**First published:**

24/01/2011

**Last updated:**

24/01/2011

[View](/el/documents/overview/prepandemic-influenza-vaccine-h5n1-surface-antigen-inactivated-adjuvanted-novartis-vaccines-and-diagnostics-epar-summary-public_el.pdf)

français (FR) (269.39 KB - PDF)

**First published:**

24/01/2011

**Last updated:**

24/01/2011

[View](/fr/documents/overview/prepandemic-influenza-vaccine-h5n1-surface-antigen-inactivated-adjuvanted-novartis-vaccines-and-diagnostics-epar-summary-public_fr.pdf)

italiano (IT) (208.27 KB - PDF)

**First published:**

24/01/2011

**Last updated:**

24/01/2011

[View](/it/documents/overview/prepandemic-influenza-vaccine-h5n1-surface-antigen-inactivated-adjuvanted-novartis-vaccines-and-diagnostics-epar-summary-public_it.pdf)

latviešu valoda (LV) (258.67 KB - PDF)

**First published:**

24/01/2011

**Last updated:**

24/01/2011

[View](/lv/documents/overview/prepandemic-influenza-vaccine-h5n1-surface-antigen-inactivated-adjuvanted-novartis-vaccines-and-diagnostics-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (237.75 KB - PDF)

**First published:**

24/01/2011

**Last updated:**

24/01/2011

[View](/lt/documents/overview/prepandemic-influenza-vaccine-h5n1-surface-antigen-inactivated-adjuvanted-novartis-vaccines-and-diagnostics-epar-summary-public_lt.pdf)

magyar (HU) (319.69 KB - PDF)

**First published:**

24/01/2011

**Last updated:**

24/01/2011

[View](/hu/documents/overview/prepandemic-influenza-vaccine-h5n1-surface-antigen-inactivated-adjuvanted-novartis-vaccines-and-diagnostics-epar-summary-public_hu.pdf)

Malti (MT) (262.34 KB - PDF)

**First published:**

24/01/2011

**Last updated:**

24/01/2011

[View](/mt/documents/overview/prepandemic-influenza-vaccine-h5n1-surface-antigen-inactivated-adjuvanted-novartis-vaccines-and-diagnostics-epar-summary-public_mt.pdf)

Nederlands (NL) (268.22 KB - PDF)

**First published:**

24/01/2011

**Last updated:**

24/01/2011

[View](/nl/documents/overview/prepandemic-influenza-vaccine-h5n1-surface-antigen-inactivated-adjuvanted-novartis-vaccines-and-diagnostics-epar-summary-public_nl.pdf)

polski (PL) (261.7 KB - PDF)

**First published:**

24/01/2011

**Last updated:**

24/01/2011

[View](/pl/documents/overview/prepandemic-influenza-vaccine-h5n1-surface-antigen-inactivated-adjuvanted-novartis-vaccines-and-diagnostics-epar-summary-public_pl.pdf)

português (PT) (265.75 KB - PDF)

**First published:**

24/01/2011

**Last updated:**

24/01/2011

[View](/pt/documents/overview/prepandemic-influenza-vaccine-h5n1-surface-antigen-inactivated-adjuvanted-novartis-vaccines-and-diagnostics-epar-summary-public_pt.pdf)

română (RO) (297.41 KB - PDF)

**First published:**

24/01/2011

**Last updated:**

24/01/2011

[View](/ro/documents/overview/prepandemic-influenza-vaccine-h5n1-surface-antigen-inactivated-adjuvanted-novartis-vaccines-and-diagnostics-epar-summary-public_ro.pdf)

slovenčina (SK) (260.16 KB - PDF)

**First published:**

24/01/2011

**Last updated:**

24/01/2011

[View](/sk/documents/overview/prepandemic-influenza-vaccine-h5n1-surface-antigen-inactivated-adjuvanted-novartis-vaccines-and-diagnostics-epar-summary-public_sk.pdf)

slovenščina (SL) (313.68 KB - PDF)

**First published:**

24/01/2011

**Last updated:**

24/01/2011

[View](/sl/documents/overview/prepandemic-influenza-vaccine-h5n1-surface-antigen-inactivated-adjuvanted-novartis-vaccines-and-diagnostics-epar-summary-public_sl.pdf)

Suomi (FI) (286.19 KB - PDF)

**First published:**

24/01/2011

**Last updated:**

24/01/2011

[View](/fi/documents/overview/prepandemic-influenza-vaccine-h5n1-surface-antigen-inactivated-adjuvanted-novartis-vaccines-and-diagnostics-epar-summary-public_fi.pdf)

svenska (SV) (281.56 KB - PDF)

**First published:**

24/01/2011

**Last updated:**

24/01/2011

[View](/sv/documents/overview/prepandemic-influenza-vaccine-h5n1-surface-antigen-inactivated-adjuvanted-novartis-vaccines-and-diagnostics-epar-summary-public_sv.pdf)

## Product information

Prepandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics : EPAR - Product Information

English (EN) (469.74 KB - PDF)

**First published:** 24/01/2011

**Last updated:** 11/09/2015

[View](/en/documents/product-information/prepandemic-influenza-vaccine-h5n1-surface-antigen-inactivated-adjuvanted-novartis-vaccines-and-diagnostics-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-483)

български (BG) (965.94 KB - PDF)

**First published:**

24/01/2011

**Last updated:**

11/09/2015

[View](/bg/documents/product-information/prepandemic-influenza-vaccine-h5n1-surface-antigen-inactivated-adjuvanted-novartis-vaccines-and-diagnostics-epar-product-information_bg.pdf)

español (ES) (525.37 KB - PDF)

**First published:**

24/01/2011

**Last updated:**

11/09/2015

[View](/es/documents/product-information/prepandemic-influenza-vaccine-h5n1-surface-antigen-inactivated-adjuvanted-novartis-vaccines-and-diagnostics-epar-product-information_es.pdf)

čeština (CS) (778.53 KB - PDF)

**First published:**

24/01/2011

**Last updated:**

11/09/2015

[View](/cs/documents/product-information/prepandemic-influenza-vaccine-h5n1-surface-antigen-inactivated-adjuvanted-novartis-vaccines-and-diagnostics-epar-product-information_cs.pdf)

dansk (DA) (487.65 KB - PDF)

**First published:**

24/01/2011

**Last updated:**

11/09/2015

[View](/da/documents/product-information/prepandemic-influenza-vaccine-h5n1-surface-antigen-inactivated-adjuvanted-novartis-vaccines-and-diagnostics-epar-product-information_da.pdf)

Deutsch (DE) (521.63 KB - PDF)

**First published:**

24/01/2011

**Last updated:**

11/09/2015

[View](/de/documents/product-information/prepandemic-influenza-vaccine-h5n1-surface-antigen-inactivated-adjuvanted-novartis-vaccines-and-diagnostics-epar-product-information_de.pdf)

eesti keel (ET) (516.89 KB - PDF)

**First published:**

24/01/2011

**Last updated:**

11/09/2015

[View](/et/documents/product-information/prepandemic-influenza-vaccine-h5n1-surface-antigen-inactivated-adjuvanted-novartis-vaccines-and-diagnostics-epar-product-information_et.pdf)

ελληνικά (EL) (968.06 KB - PDF)

**First published:**

24/01/2011

**Last updated:**

11/09/2015

[View](/el/documents/product-information/prepandemic-influenza-vaccine-h5n1-surface-antigen-inactivated-adjuvanted-novartis-vaccines-and-diagnostics-epar-product-information_el.pdf)

français (FR) (673.28 KB - PDF)

**First published:**

24/01/2011

**Last updated:**

11/09/2015

[View](/fr/documents/product-information/prepandemic-influenza-vaccine-h5n1-surface-antigen-inactivated-adjuvanted-novartis-vaccines-and-diagnostics-epar-product-information_fr.pdf)

hrvatski (HR) (148.88 KB - PDF)

**First published:**

24/01/2011

**Last updated:**

11/09/2015

[View](/hr/documents/product-information/prepandemic-influenza-vaccine-h5n1-surface-antigen-inactivated-adjuvanted-novartis-vaccines-and-diagnostics-epar-product-information_hr.pdf)

íslenska (IS) (518.39 KB - PDF)

**First published:**

24/01/2011

**Last updated:**

11/09/2015

[View](/is/documents/product-information/prepandemic-influenza-vaccine-h5n1-surface-antigen-inactivated-adjuvanted-novartis-vaccines-and-diagnostics-epar-product-information_is.pdf)

italiano (IT) (562.29 KB - PDF)

**First published:**

24/01/2011

**Last updated:**

11/09/2015

[View](/it/documents/product-information/prepandemic-influenza-vaccine-h5n1-surface-antigen-inactivated-adjuvanted-novartis-vaccines-and-diagnostics-epar-product-information_it.pdf)

latviešu valoda (LV) (795.01 KB - PDF)

**First published:**

24/01/2011

**Last updated:**

11/09/2015

[View](/lv/documents/product-information/prepandemic-influenza-vaccine-h5n1-surface-antigen-inactivated-adjuvanted-novartis-vaccines-and-diagnostics-epar-product-information_lv.pdf)

lietuvių kalba (LT) (603.35 KB - PDF)

**First published:**

24/01/2011

**Last updated:**

11/09/2015

[View](/lt/documents/product-information/prepandemic-influenza-vaccine-h5n1-surface-antigen-inactivated-adjuvanted-novartis-vaccines-and-diagnostics-epar-product-information_lt.pdf)

magyar (HU) (771.06 KB - PDF)

**First published:**

24/01/2011

**Last updated:**

11/09/2015

[View](/hu/documents/product-information/prepandemic-influenza-vaccine-h5n1-surface-antigen-inactivated-adjuvanted-novartis-vaccines-and-diagnostics-epar-product-information_hu.pdf)

Malti (MT) (806.13 KB - PDF)

**First published:**

24/01/2011

**Last updated:**

11/09/2015

[View](/mt/documents/product-information/prepandemic-influenza-vaccine-h5n1-surface-antigen-inactivated-adjuvanted-novartis-vaccines-and-diagnostics-epar-product-information_mt.pdf)

Nederlands (NL) (499.63 KB - PDF)

**First published:**

24/01/2011

**Last updated:**

11/09/2015

[View](/nl/documents/product-information/prepandemic-influenza-vaccine-h5n1-surface-antigen-inactivated-adjuvanted-novartis-vaccines-and-diagnostics-epar-product-information_nl.pdf)

norsk (NO) (474.67 KB - PDF)

**First published:**

24/01/2011

**Last updated:**

11/09/2015

[View](/no/documents/product-information/prepandemic-influenza-vaccine-h5n1-surface-antigen-inactivated-adjuvanted-novartis-vaccines-and-diagnostics-epar-product-information_no.pdf)

polski (PL) (799.79 KB - PDF)

**First published:**

24/01/2011

**Last updated:**

11/09/2015

[View](/pl/documents/product-information/prepandemic-influenza-vaccine-h5n1-surface-antigen-inactivated-adjuvanted-novartis-vaccines-and-diagnostics-epar-product-information_pl.pdf)

português (PT) (526.89 KB - PDF)

**First published:**

24/01/2011

**Last updated:**

11/09/2015

[View](/pt/documents/product-information/prepandemic-influenza-vaccine-h5n1-surface-antigen-inactivated-adjuvanted-novartis-vaccines-and-diagnostics-epar-product-information_pt.pdf)

română (RO) (618.29 KB - PDF)

**First published:**

24/01/2011

**Last updated:**

11/09/2015

[View](/ro/documents/product-information/prepandemic-influenza-vaccine-h5n1-surface-antigen-inactivated-adjuvanted-novartis-vaccines-and-diagnostics-epar-product-information_ro.pdf)

slovenčina (SK) (800.75 KB - PDF)

**First published:**

24/01/2011

**Last updated:**

11/09/2015

[View](/sk/documents/product-information/prepandemic-influenza-vaccine-h5n1-surface-antigen-inactivated-adjuvanted-novartis-vaccines-and-diagnostics-epar-product-information_sk.pdf)

slovenščina (SL) (769.69 KB - PDF)

**First published:**

24/01/2011

**Last updated:**

11/09/2015

[View](/sl/documents/product-information/prepandemic-influenza-vaccine-h5n1-surface-antigen-inactivated-adjuvanted-novartis-vaccines-and-diagnostics-epar-product-information_sl.pdf)

Suomi (FI) (525.78 KB - PDF)

**First published:**

24/01/2011

**Last updated:**

11/09/2015

[View](/fi/documents/product-information/prepandemic-influenza-vaccine-h5n1-surface-antigen-inactivated-adjuvanted-novartis-vaccines-and-diagnostics-epar-product-information_fi.pdf)

svenska (SV) (524.97 KB - PDF)

**First published:**

24/01/2011

**Last updated:**

11/09/2015

[View](/sv/documents/product-information/prepandemic-influenza-vaccine-h5n1-surface-antigen-inactivated-adjuvanted-novartis-vaccines-and-diagnostics-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** PSUSA/10008 28/07/2015

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Prepandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics : EPAR - All Authorised presentations

English (EN) (144.99 KB - PDF)

**First published:** 24/01/2011

**Last updated:** 24/01/2011

[View](/en/documents/all-authorised-presentations/prepandemic-influenza-vaccine-h5n1-surface-antigen-inactivated-adjuvanted-novartis-vaccines-and-diagnostics-epar-all-authorised-presentations_en.pdf)

[Other languages (21)](#file-language-dropdown-628)

български (BG) (238.92 KB - PDF)

**First published:**

24/01/2011

**Last updated:**

24/01/2011

[View](/bg/documents/all-authorised-presentations/prepandemic-influenza-vaccine-h5n1-surface-antigen-inactivated-adjuvanted-novartis-vaccines-and-diagnostics-epar-all-authorised-presentations_bg.pdf)

español (ES) (146.15 KB - PDF)

**First published:**

24/01/2011

**Last updated:**

24/01/2011

[View](/es/documents/all-authorised-presentations/prepandemic-influenza-vaccine-h5n1-surface-antigen-inactivated-adjuvanted-novartis-vaccines-and-diagnostics-epar-all-authorised-presentations_es.pdf)

čeština (CS) (226.93 KB - PDF)

**First published:**

24/01/2011

**Last updated:**

24/01/2011

[View](/cs/documents/all-authorised-presentations/prepandemic-influenza-vaccine-h5n1-surface-antigen-inactivated-adjuvanted-novartis-vaccines-and-diagnostics-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (145.8 KB - PDF)

**First published:**

24/01/2011

**Last updated:**

24/01/2011

[View](/da/documents/all-authorised-presentations/prepandemic-influenza-vaccine-h5n1-surface-antigen-inactivated-adjuvanted-novartis-vaccines-and-diagnostics-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (145.14 KB - PDF)

**First published:**

24/01/2011

**Last updated:**

24/01/2011

[View](/de/documents/all-authorised-presentations/prepandemic-influenza-vaccine-h5n1-surface-antigen-inactivated-adjuvanted-novartis-vaccines-and-diagnostics-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (145.7 KB - PDF)

**First published:**

24/01/2011

**Last updated:**

24/01/2011

[View](/et/documents/all-authorised-presentations/prepandemic-influenza-vaccine-h5n1-surface-antigen-inactivated-adjuvanted-novartis-vaccines-and-diagnostics-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (233.06 KB - PDF)

**First published:**

24/01/2011

**Last updated:**

24/01/2011

[View](/el/documents/all-authorised-presentations/prepandemic-influenza-vaccine-h5n1-surface-antigen-inactivated-adjuvanted-novartis-vaccines-and-diagnostics-epar-all-authorised-presentations_el.pdf)

français (FR) (145.09 KB - PDF)

**First published:**

24/01/2011

**Last updated:**

24/01/2011

[View](/fr/documents/all-authorised-presentations/prepandemic-influenza-vaccine-h5n1-surface-antigen-inactivated-adjuvanted-novartis-vaccines-and-diagnostics-epar-all-authorised-presentations_fr.pdf)

italiano (IT) (144.49 KB - PDF)

**First published:**

24/01/2011

**Last updated:**

24/01/2011

[View](/it/documents/all-authorised-presentations/prepandemic-influenza-vaccine-h5n1-surface-antigen-inactivated-adjuvanted-novartis-vaccines-and-diagnostics-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (223.06 KB - PDF)

**First published:**

24/01/2011

**Last updated:**

24/01/2011

[View](/lv/documents/all-authorised-presentations/prepandemic-influenza-vaccine-h5n1-surface-antigen-inactivated-adjuvanted-novartis-vaccines-and-diagnostics-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (215.35 KB - PDF)

**First published:**

24/01/2011

**Last updated:**

24/01/2011

[View](/lt/documents/all-authorised-presentations/prepandemic-influenza-vaccine-h5n1-surface-antigen-inactivated-adjuvanted-novartis-vaccines-and-diagnostics-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (222.98 KB - PDF)

**First published:**

24/01/2011

**Last updated:**

24/01/2011

[View](/hu/documents/all-authorised-presentations/prepandemic-influenza-vaccine-h5n1-surface-antigen-inactivated-adjuvanted-novartis-vaccines-and-diagnostics-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (230.08 KB - PDF)

**First published:**

24/01/2011

**Last updated:**

24/01/2011

[View](/mt/documents/all-authorised-presentations/prepandemic-influenza-vaccine-h5n1-surface-antigen-inactivated-adjuvanted-novartis-vaccines-and-diagnostics-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (145.36 KB - PDF)

**First published:**

24/01/2011

**Last updated:**

24/01/2011

[View](/nl/documents/all-authorised-presentations/prepandemic-influenza-vaccine-h5n1-surface-antigen-inactivated-adjuvanted-novartis-vaccines-and-diagnostics-epar-all-authorised-presentations_nl.pdf)

polski (PL) (228.03 KB - PDF)

**First published:**

24/01/2011

**Last updated:**

24/01/2011

[View](/pl/documents/all-authorised-presentations/prepandemic-influenza-vaccine-h5n1-surface-antigen-inactivated-adjuvanted-novartis-vaccines-and-diagnostics-epar-all-authorised-presentations_pl.pdf)

português (PT) (144.99 KB - PDF)

**First published:**

24/01/2011

**Last updated:**

24/01/2011

[View](/pt/documents/all-authorised-presentations/prepandemic-influenza-vaccine-h5n1-surface-antigen-inactivated-adjuvanted-novartis-vaccines-and-diagnostics-epar-all-authorised-presentations_pt.pdf)

română (RO) (218.05 KB - PDF)

**First published:**

24/01/2011

**Last updated:**

24/01/2011

[View](/ro/documents/all-authorised-presentations/prepandemic-influenza-vaccine-h5n1-surface-antigen-inactivated-adjuvanted-novartis-vaccines-and-diagnostics-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (225.92 KB - PDF)

**First published:**

24/01/2011

**Last updated:**

24/01/2011

[View](/sk/documents/all-authorised-presentations/prepandemic-influenza-vaccine-h5n1-surface-antigen-inactivated-adjuvanted-novartis-vaccines-and-diagnostics-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (150.71 KB - PDF)

**First published:**

24/01/2011

**Last updated:**

24/01/2011

[View](/sl/documents/all-authorised-presentations/prepandemic-influenza-vaccine-h5n1-surface-antigen-inactivated-adjuvanted-novartis-vaccines-and-diagnostics-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (145.43 KB - PDF)

**First published:**

24/01/2011

**Last updated:**

24/01/2011

[View](/fi/documents/all-authorised-presentations/prepandemic-influenza-vaccine-h5n1-surface-antigen-inactivated-adjuvanted-novartis-vaccines-and-diagnostics-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (145.49 KB - PDF)

**First published:**

24/01/2011

**Last updated:**

24/01/2011

[View](/sv/documents/all-authorised-presentations/prepandemic-influenza-vaccine-h5n1-surface-antigen-inactivated-adjuvanted-novartis-vaccines-and-diagnostics-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Prepandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics Active substance influenza virus surface antigens (haemagglutinin and neuraminidase) of strain A/Viet Nam/1194/2004 (H5N1) International non-proprietary name (INN) or common name prepandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Therapeutic area (MeSH)

- Influenza, Human
- Immunization
- Disease Outbreaks

Anatomical therapeutic chemical (ATC) code J07BB02

### Pharmacotherapeutic group

Vaccines

### Therapeutic indication

Active immunisation against H5N1 subtype of Influenza A virus.

This indication is based on immunogenicity data from healthy subjects from the age of 18 years onwards following administration of two doses of the vaccine containing A/Vietnam/1194/2004 (H5N1)-like strain.

Prepandemic influenza vaccine (H5N1) Novartis Vaccines and Diagnostic should be used in accordance with official recommendations.

## Authorisation details

EMA product number EMEA/H/C/002269 Marketing authorisation holder

Novartis Vaccines and Diagnostics S.r.l.

Via Fiorentina, 1

Marketing authorisation issued 29/11/2010 Expiry of marketing authorisation 28/11/2015 Revision 2

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Prepandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (242.18 KB - PDF)

**First published:** 04/04/2012

**Last updated:** 11/09/2015

[View](/en/documents/procedural-steps-after/prepandemic-influenza-vaccine-h5n1-surface-antigen-inactivated-adjuvanted-novartis-vaccines-and-diagnostics-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf)

Prepandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics-H-C-PSUSA-00010008/201410 : EPAR - Scientific conclusions and grounds recommending the variation to the te...

English (EN) (202.7 KB - PDF)

**First published:** 11/09/2015

**Last updated:** 11/09/2015

[View](/en/documents/scientific-conclusion/prepandemic-influenza-vaccine-h5n1-surface-antigen-inactivated-adjuvanted-novartis-vaccines-and-diagnostics-h-c-psusa-00010008201410-epar-scientific-conclusions-and-grounds-recommending-variation-te_en.pdf)

## Initial marketing authorisation documents

Prepandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics : EPAR - Public assessment report

English (EN) (1.42 MB - PDF)

**First published:** 24/01/2011

**Last updated:** 24/01/2011

[View](/en/documents/assessment-report/prepandemic-influenza-vaccine-h5n1-surface-antigen-inactivated-adjuvanted-novartis-vaccines-and-diagnostics-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Prepandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics

Adopted

Reference Number: EMA/CHMP/597536/2010

English (EN) (204.59 KB - PDF)

**First published:** 24/09/2010

**Last updated:** 24/09/2010

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-prepandemic-influenza-vaccine-h5n1-surface-antigen-inactivated-adjuvanted-novartis-vaccines-and-diagnostics_en.pdf)

**This page was last updated on** 07/03/2016

## Share this page

[Back to top](#main-content)